Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Um estudo clínico de combinações de tratamento baseadas em deruxtecan ifinatamab ou como monoterapia para tratar o câncer de próstata resistente à castrato metastático (MCRPC) (MK-2400-01A/IDEATE-PROSTATE02)

8 de outubro de 2026 atualizado por: Merck Sharp & Dohme LLC

Substudy MK-2400-01A: um substituto de fase 1/2, guarda-chuva aberta do protocolo mestre MK-2400-U01 para avaliar a segurança e a eficácia das combinações de tratamento baseadas em deruxtecan (resstrinhas de deruxtatic-resstratante (resstrinhas) (resstrinhas de itenscan) (resstrinhas de itenstica (resstrato) (resstrato) (resstrato) (resstrato de trimestrc) (resstrato de trimestrecan) (resstrato de resstrato de ifinatamab somente em particular com base em itenstica-resumo (resstrião) (resstrato de resseptica de meta-resistente (resstrinhas) (resstrinhas de resseptio-resistente (resstrato de ifinatamab apenas em participantes com a resseptação por metastáticos-resseptores (resseptos de sugestão de meta-resistente.

The purpose of this substudy is to assess the efficacy and safety of ifinatamab deruxtecan (I-DXd), given alone or with other treatments in participants with metastatic castration-resistant prostate cancer (mCRPC). The goals of this study are to learn about:

  • The safety of the study treatment and if people tolerate it.
  • A safe dose level of I-DXd that can be used with other treatments.
  • Participant levels of prostate specific antigen (PSA) during treatment.

Visão geral do estudo

Descrição detalhada

This sub study MK-2400-01A assesses treatments for metastatic castration-resistant prostate cancer (mCRPC).

The master screening protocol is MK-2400-U01

Tipo de estudo

Intervencional

Inscrição (Estimado)

360

Estágio

  • Fase 2
  • Fase 1

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Locais de estudo

      • Hamburg, Alemanha, 20246
        • Recrutamento
        • Universitaetsklinikum Hamburg-Eppendorf ( Site 0524)
        • Contato:
          • Study Coordinator
          • Número de telefone: +4915222815585
    • Baden-Wurttemberg
      • Heidelberg, Baden-Wurttemberg, Alemanha, 69120
        • Recrutamento
        • NCT ( Site 0528)
        • Contato:
          • Study Coordinator
          • Número de telefone: 00496221566857
      • Ulm, Baden-Wurttemberg, Alemanha, 89081
        • Recrutamento
        • Universitaetsklinikum Ulm. ( Site 0530)
        • Contato:
          • Study Coordinator
          • Número de telefone: +4973150058188
    • Thuringia
      • Jena, Thuringia, Alemanha, 07747
        • Recrutamento
        • Universitaetsklinikum Jena ( Site 0525)
        • Contato:
          • Study Coordinator
          • Número de telefone: +49-3641-9-329901
      • La Rioja, Argentina, F5300COE
        • Recrutamento
        • Fundación CORI para la Investigación y Prevención del Cáncer ( Site 0200)
        • Contato:
          • Study Coordinator
          • Número de telefone: 54-380-443-6443
    • Buenos Aires
      • Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, C1426ANZ
        • Recrutamento
        • Instituto Alexander Fleming ( Site 0202)
        • Contato:
          • Study Coordinator
          • Número de telefone: 5411 3221 8900
    • New South Wales
      • Macquarie University, New South Wales, Austrália, 2109
        • Recrutamento
        • Macquarie University-MQ Health Clinical Trials Unit ( Site 0801)
        • Contato:
          • Study Coordinator
          • Número de telefone: +61 2 9812 2956
      • São Paulo, Brasil, 01221-020
        • Recrutamento
        • IPITEC ( Site 0275)
        • Contato:
          • Study Coordinator
          • Número de telefone: +551194322-6006
      • São Paulo, Brasil, 03102-006
        • Recrutamento
        • IBCC - Instituto Brasileiro de Controle do Câncer ( Site 0269)
        • Contato:
          • Study Coordinator
          • Número de telefone: +551144500360
    • Rio Grande do Norte
      • Natal, Rio Grande do Norte, Brasil, 59062-000
        • Recrutamento
        • Liga Norte Riograndense Contra o Câncer ( Site 0271)
        • Contato:
          • Study Coordinator
          • Número de telefone: (84) 4009-5595
    • Rio Grande do Sul
      • Porto Alegre, Rio Grande do Sul, Brasil, 90035-001
        • Recrutamento
        • Hospital Moinhos de Vento ( Site 0278)
        • Contato:
          • Study Coordinator
          • Número de telefone: +55 51 3314-3209
      • Porto Alegre, Rio Grande do Sul, Brasil, 90020-090
        • Recrutamento
        • Irmandade da Santa Casa de Misericórdia de Porto Alegre ( Site 0270)
        • Contato:
          • Study Coordinator
          • Número de telefone: +555132148151
    • São Paulo
      • Bragança Paulista, São Paulo, Brasil, 12916-542
        • Recrutamento
        • Hospital Universitário São Francisco de Assis - Bragança Paulista ( Site 0268)
        • Contato:
          • Study Coordinator
          • Número de telefone: +551124901366
      • Ribeirão Preto, São Paulo, Brasil, 14048900
        • Recrutamento
        • Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo (USP) ( Site 0273)
        • Contato:
          • Study Coordinator
          • Número de telefone: (16) 3963-6487
      • São José do Rio Preto, São Paulo, Brasil, 15090-000
        • Recrutamento
        • Fundação Faculdade Regional de Medicina de São José do Rio Preto ( Site 0263)
        • Contato:
          • Study Coordinator
          • Número de telefone: +55 17 99625-3919
      • São Paulo, São Paulo, Brasil, 01327-001
        • Recrutamento
        • Hospital Alemao Oswaldo Cruz ( Site 0279)
        • Contato:
          • Study Coordinator
          • Número de telefone: 55 11 3549-0009
    • British Columbia
      • Vancouver, British Columbia, Canadá, V5Z 4E6
        • Recrutamento
        • BC Cancer - Vancouver Center ( Site 0103)
        • Contato:
          • Study Coordinator
          • Número de telefone: 6048776000
    • Ontario
      • Toronto, Ontario, Canadá, M4N 3M5
        • Recrutamento
        • Sunnybrook Research Institute ( Site 0109)
        • Contato:
          • Study Coordinator
          • Número de telefone: 4164806100
      • Toronto, Ontario, Canadá, M5G 2M9
        • Recrutamento
        • Princess Margaret Cancer Centre ( Site 0102)
        • Contato:
          • Study Coordinator
          • Número de telefone: 4169464501
    • Quebec
      • Montreal, Quebec, Canadá, H3T 1E2
        • Recrutamento
        • Jewish General Hospital ( Site 0108)
        • Contato:
          • Study Coordinator
          • Número de telefone: 5143408110
      • Sherbrooke, Quebec, Canadá, J1H 5N4
        • Recrutamento
        • CIUSSS de l Estrie - CHUS - Centre Hosp. Univ. Sherbrooke ( Site 0107)
        • Contato:
          • Study Coordinator
          • Número de telefone: 8197802222
    • Maule Region
      • Talca, Maule Region, Chile, 3465584
        • Recrutamento
        • Clinica Universidad Catolica del Maule ( Site 0236)
        • Contato:
          • Study Coordinator
          • Número de telefone: 56992992913
    • Region M. de Santiago
      • Santiago, Region M. de Santiago, Chile, 8420383
        • Recrutamento
        • Bradfordhill ( Site 0231)
        • Contato:
          • Study Coordinator
          • Número de telefone: +56229490970
      • Santiago, Region M. de Santiago, Chile, 7560908
        • Recrutamento
        • Centro de Oncología de Precisión ( Site 0241)
        • Contato:
          • Study Coordinator
          • Número de telefone: +56225189885
      • Santiago, Region M. de Santiago, Chile, 7500921
        • Recrutamento
        • Fundación Arturo López Pérez ( Site 0232)
        • Contato:
          • Study Coordinator
          • Número de telefone: 56224205098
    • Valparaiso
      • Viña del Mar, Valparaiso, Chile, 2520598
        • Recrutamento
        • ONCOCENTRO APYS ( Site 0234)
        • Contato:
          • Study Coordinator
          • Número de telefone: +56323320850
      • Seoul, Coréia do Sul, 06351
        • Recrutamento
        • Samsung Medical Center ( Site 0926)
        • Contato:
          • Study Coordinator
          • Número de telefone: +82234103459
      • Seoul, Coréia do Sul, 03722
        • Ativo, não recrutando
        • Severance Hospital Yonsei University Health System ( Site 0924)
    • Seoul
      • Songpagu, Seoul, Coréia do Sul, 05505
        • Recrutamento
        • Asan Medical Center ( Site 0925)
        • Contato:
          • Study Coordinator
          • Número de telefone: +82230105977
      • Madrid, Espanha, 28034
        • Recrutamento
        • Hospital Universitario Ramon y Cajal ( Site 0620)
        • Contato:
          • Study Coordinator
          • Número de telefone: +34913368263
      • Madrid, Espanha, 28041
        • Recrutamento
        • Hospital Universitario 12 de Octubre ( Site 0622)
        • Contato:
          • Study Coordinator
          • Número de telefone: +34608464547
      • Madrid, Espanha, 28040
        • Recrutamento
        • Hospital Clinico San Carlos ( Site 0618)
        • Contato:
          • Study Coordinator
          • Número de telefone: +34913303546
      • Seville, Espanha, 41013
        • Recrutamento
        • Hospital Universitario Virgen del Rocio ( Site 0619)
        • Contato:
          • Study Coordinator
          • Número de telefone: +34955013068
    • Barcelona
      • L Hospitalet Del Llobregat, Barcelona, Espanha, 08908
        • Recrutamento
        • ICO L Hospitalet ( Site 0617)
        • Contato:
          • Study Coordinator
          • Número de telefone: +34932607744
    • California
      • Los Angeles, California, Estados Unidos, 90095
        • Recrutamento
        • UCLA Hematology & Oncology ( Site 0003)
        • Contato:
          • Study Coordinator
          • Número de telefone: 310-829-5471
      • Orange, California, Estados Unidos, 92868
        • Recrutamento
        • University of California-Irvine Medical Center ( Site 0016)
        • Contato:
          • Study Coordinator
          • Número de telefone: 714-456-5153
      • San Francisco, California, Estados Unidos, 94158
        • Recrutamento
        • UCSF Medical Center at Mission Bay ( Site 0034)
        • Contato:
          • Study Coordinator
          • Número de telefone: 415-502-2097
    • District of Columbia
      • Washington D.C., District of Columbia, Estados Unidos, 20010
        • Recrutamento
        • MedStar Georgetown Cancer Institute at MedStar Washington Hospital Center ( Site 0026)
        • Contato:
          • Study Coordinator
          • Número de telefone: 202-877-3061
    • Michigan
      • Ann Arbor, Michigan, Estados Unidos, 48109
        • Recrutamento
        • University of Michigan ( Site 0021)
        • Contato:
          • Study Coordinator
          • Número de telefone: 734-936-4000
    • New York
      • New York, New York, Estados Unidos, 10065
        • Recrutamento
        • Memorial Sloan Kettering Cancer Center ( Site 0006)
        • Contato:
          • Study Coordinator
          • Número de telefone: 347-798-8620
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Estados Unidos, 15232
        • Recrutamento
        • UPMC Hillman Cancer Center ( Site 0014)
        • Contato:
          • Study Coordinator
          • Número de telefone: 412-647-2811
    • Tennessee
      • Germantown, Tennessee, Estados Unidos, 38138
        • Recrutamento
        • The West Clinic, PLLC dba West Cancer Center ( Site 0005)
        • Contato:
          • Study Coordinator
          • Número de telefone: 901-683-0055
    • Washington
      • Seattle, Washington, Estados Unidos, 98109
        • Recrutamento
        • Fred Hutchinson Cancer Center ( Site 0013)
        • Contato:
          • Study Coordinator
          • Número de telefone: 206-288-1111
    • Gironde
      • Bordeaux, Gironde, França, 33000
        • Recrutamento
        • Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest ( Site 0498)
        • Contato:
          • Study Coordinator
          • Número de telefone: +33556333261
    • Nord
      • Lille, Nord, França, 59000
        • Recrutamento
        • Centre Oscar Lambret ( Site 0495)
        • Contato:
          • Study Coordinator
          • Número de telefone: +333 20 29 56 06
    • Pays de la Loire Region
      • Saint-Herblain, Pays de la Loire Region, França, 44800
        • Recrutamento
        • Institut De Cancerologie De L Ouest ( Site 0494)
        • Contato:
          • Study Coordinator
          • Número de telefone: +33240679900
    • Pyrenees-Atlantiques
      • Bayonne, Pyrenees-Atlantiques, França, 64100
        • Recrutamento
        • Centre Hospitalier de la Cote Basque ( Site 0496)
        • Contato:
          • Study Coordinator
          • Número de telefone: +33559443762
    • Rhone
      • Pierre-Bénite, Rhone, França, 69310
        • Recrutamento
        • centre hospitalier lyon sud ( Site 0497)
        • Contato:
          • Study Coordinator
          • Número de telefone: 33 4 78 86 43 24
    • Gelderland
      • Ede, Gelderland, Holanda, 6716 RP
        • Recrutamento
        • Ziekenhuis Gelderse Vallei ( Site 0683)
        • Contato:
          • Study Coordinator
          • Número de telefone: +31 318 435499
      • Nijmegen, Gelderland, Holanda, 6525 GA
        • Recrutamento
        • UMC St. Radboud ( Site 0679)
        • Contato:
          • Study Coordinator
          • Número de telefone: +31 24 361 1111
    • Provincie Friesland
      • Drachten, Provincie Friesland, Holanda, 9202 NN
        • Recrutamento
        • Nij Smellinghe ( Site 0684)
        • Contato:
          • Study Coordinator
          • Número de telefone: 0512 588 888
      • Dublin, Irlanda, D09 V2N0
        • Recrutamento
        • Beaumont Hospital, Dublin ( Site 0465)
        • Contato:
          • Study Coordinator
          • Número de telefone: 0035318092010
      • Dublin, Irlanda, D24 NR0A
        • Recrutamento
        • Tallaght University Hospital ( Site 0462)
        • Contato:
          • Study Coordinator
          • Número de telefone: 0035314144209
    • Dublin
      • Dublin, Dublin, Irlanda, D04 T6F4
        • Recrutamento
        • St Vincent's University Hospital ( Site 0463)
        • Contato:
          • Study Coordinator
          • Número de telefone: +353 1 221 4982
      • Haifa, Israel, 3109601
        • Recrutamento
        • Rambam Health Care Campus ( Site 0400)
        • Contato:
          • Study Coordinator
          • Número de telefone: 972(47776234)
      • Jerusalem, Israel, 9112001
        • Recrutamento
        • Hadassah Medical Center ( Site 0404)
        • Contato:
          • Study Coordinator
          • Número de telefone: +97226777333
      • Petah Tikva, Israel, 4941492
        • Recrutamento
        • Rabin Medical Center ( Site 0402)
        • Contato:
          • Study Coordinator
          • Número de telefone: +972544594048
      • Ramat Gan, Israel, 5265601
        • Recrutamento
        • Sheba Medical Center ( Site 0401)
        • Contato:
          • Study Coordinator
          • Número de telefone: +97235303030
      • Tel Aviv, Israel, 6423906
        • Recrutamento
        • Sourasky Medical Center ( Site 0403)
        • Contato:
          • Study Coordinator
          • Número de telefone: +97236947832
      • Brescia, Itália, 25123
        • Ativo, não recrutando
        • Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia ( Site 0432)
      • Milan, Itália, 20133
        • Recrutamento
        • Fondazione IRCCS Istituto Nazionale Dei Tumori ( Site 0431)
        • Contato:
          • Study Coordinator
          • Número de telefone: +390223904449
      • Naples, Itália, 80131
        • Recrutamento
        • A.O.U. Federico II di Napoli ( Site 0435)
        • Contato:
          • Study Coordinator
          • Número de telefone: +390817463660
      • Roma, Itália, 00168
        • Recrutamento
        • Fondazione Policlinico Universitario Agostino Gemelli ( Site 0433)
        • Contato:
          • Study Coordinator
          • Número de telefone: +390630155202
    • Torino
      • Orbassano, Torino, Itália, 10143
        • Recrutamento
        • AOU San Luigi Gonzaga di Orbassano ( Site 0434)
        • Contato:
          • Study Coordinator
          • Número de telefone: 00390119026534
      • Auckland, Nova Zelândia, 1023
        • Recrutamento
        • Auckland City Hospital ( Site 0831)
        • Contato:
          • Study Coordinator
          • Número de telefone: +6493074949
    • Greater Poland Voivodeship
      • Poznan, Greater Poland Voivodeship, Polônia, 60-355
        • Recrutamento
        • Uniwersytecki Szpital Kliniczny w Poznaniu ( Site 0590)
        • Contato:
          • Study Coordinator
          • Número de telefone: +61 854 79 87
    • Masovian Voivodeship
      • Warsaw, Masovian Voivodeship, Polônia, 02-781
        • Recrutamento
        • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie ( Site 0586)
        • Contato:
          • Study Coordinator
          • Número de telefone: +48 22 546 33 81
    • Pomeranian Voivodeship
      • Gdansk, Pomeranian Voivodeship, Polônia, 80-214
        • Recrutamento
        • Uniwersyteckie Centrum Kliniczne ( Site 0588)
        • Contato:
          • Study Coordinator
          • Número de telefone: +48 58 584 44 66
    • West Pomeranian Voivodeship
      • Koszalin, West Pomeranian Voivodeship, Polônia, 75-581
        • Recrutamento
        • Szpital Wojewódzki im. M.Kopernika Oddział Onk. Klinicznej z Pododdziałem Chemioterapii Jednodniowej ( Site 0587)
        • Contato:
          • Study Coordinator
          • Número de telefone: +48943488930
    • Cambridgeshire
      • Cambridge, Cambridgeshire, Reino Unido, CB2 2QQ
        • Recrutamento
        • Addenbrooke's Hospital ( Site 0747)
        • Contato:
          • Study Coordinator
          • Número de telefone: 00441223216083
    • London, City of
      • London, London, City of, Reino Unido, NW3 2QG
        • Recrutamento
        • Royal Free Hospital ( Site 0743)
        • Contato:
          • Study Coordinator
          • Número de telefone: 00442077940500/2237
      • London, London, City of, Reino Unido, EC1A 7BE
        • Recrutamento
        • St Bartholomew's Hospital ( Site 0749)
        • Contato:
          • Study Coordinator
          • Número de telefone: 00442073777000
    • Surrey
      • London, Surrey, Reino Unido, SM3 5PT
        • Recrutamento
        • Royal Marsden Hospital (Sutton) ( Site 0741)
        • Contato:
          • Study Coordinator
          • Número de telefone: 0203 437 3500
      • Taichung, Taiwan, 40705
        • Recrutamento
        • Taichung Veterans General Hospital ( Site 0902)
        • Contato:
          • Study Coordinator
          • Número de telefone: +886423592525
      • Taipei, Taiwan, 11217
        • Recrutamento
        • Taipei Veterans General Hospital ( Site 0901)
        • Contato:
          • Study Coordinator
          • Número de telefone: +886228712121
      • Adana, Turquia (Türkiye), 01250
        • Recrutamento
        • Baskent University Dr. Turgut Noyan Research and Training Center ( Site 0650)
        • Contato:
          • Study Coordinator
          • Número de telefone: +903223271274
      • Ankara, Turquia (Türkiye), 06230
        • Recrutamento
        • Hacettepe Universitesi Tip Fakultesi ( Site 0648)
        • Contato:
          • Study Coordinator
          • Número de telefone: +90 312 305 50 00
      • Ankara, Turquia (Türkiye), 06800
        • Recrutamento
        • Ankara Bilkent Şehir Hastanesi ( Site 0654)
        • Contato:
          • Study Coordinator
          • Número de telefone: +903125526000
      • Ankara, Turquia (Türkiye), 06620
        • Recrutamento
        • Ankara Universitesi Tip Fakultesi Hastanesi ( Site 0653)
        • Contato:
          • Study Coordinator
          • Número de telefone: +903122126040
      • Istanbul, Turquia (Türkiye), 34010
        • Recrutamento
        • Koç Üniversitesi Hastanesi ( Site 0656)
        • Contato:
          • Study Coordinator
          • Número de telefone: +905369410661
      • Istanbul, Turquia (Türkiye), 34098
        • Recrutamento
        • Istanbul Universitesi Cerrahpasa ( Site 0649)
        • Contato:
          • Study Coordinator
          • Número de telefone: +902124143000
      • Rize, Turquia (Türkiye), 53020
        • Recrutamento
        • Recep Tayyip Erdogan University Training and Research Hospital ( Site 0655)
        • Contato:
          • Study Coordinator
          • Número de telefone: +904642130491

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

The main inclusion criteria include but are not limited to the following:

  • Has histologically- or cytologically-confirmed adenocarcinoma of the prostate without small cell histology
  • Has prostate cancer progression while on androgen deprivation therapy (ADT) (or post bilateral orchiectomy) within 6 months before Screening
  • Has current evidence of distant metastatic disease
  • Has received prior treatment with 1 or 2 androgen receptor pathway inhibitors (ARPIs) and progressed during or after treatment
  • Participants receiving bone resorptive therapy (including, but not limited to bisphosphonate or denosumab) must have been on stable doses for ≥4 weeks before allocation/randomization
  • An Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 assessed within 10 days before allocation/randomization
  • Has prior treatment with poly-ADP-ribose polymerase inhibitors (PARPi) if indicated by local approved regimen or were deemed ineligible to receive PARPi by the investigator

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

  • Has any history of interstitial lung disease (ILD)/pneumonitis irrespective of steroid use (except for a history of radiation pneumonitis that did not require steroids), current ILD, clinical or radiographic suspicion of ILD for which the diagnosis of ILD cannot be ruled out
  • Clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses
  • Uncontrolled or significant cardiovascular disease
  • History of pituitary dysfunction
  • Poorly controlled diabetes mellitus
  • History or current condition of adrenal insufficiency (eg, Addison's disease)
  • Has received prior treatment with taxane-based chemotherapy agent for metastatic castration-resistant prostate cancer (mCRPC).
  • Chronic steroid treatment (dose of >10 mg daily prednisone equivalent), except for low-dose inhaled steroids (for asthma/chronic obstructive pulmonary disease), topical steroids (for mild skin conditions), or intra-articular steroid injections
  • Received prior radiotherapy within 2 weeks of start of study intervention, or has radiation-related toxicities, requiring corticosteroids
  • Known additional malignancy that is progressing or has required active treatment within the past 3 years
  • Known active central nervous system (CNS) metastases and/or carcinomatous meningitis
  • Active autoimmune disease that has required systemic treatment in the past 2 years
  • History of allogeneic tissue/solid organ transplant

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Comparador Ativo: Docetaxel

Participants will receive docetaxel at a determined dose every 3 weeks (Q3W) for a maximum of 10 cycles. Each cycle is 21 days.

Administered via Intravenous (IV) infusion at a specified dose on specified days

Experimental: Ifinatamab Deruxtecan (I-DXd)

Participants will receive I-DXd at a determined dose Q3W until unacceptable toxicity, progressive disease (PD), death or withdrawal of consent.

Administered via IV infusion at a specified dose on specified days

Outros nomes:
  • I-DXD, MK-2400, DS-7300A

Before each dose of I-DXd, participants are required to take premedication for prevention of nausea and vomiting with a 2- or 3-drug combination regimen (eg, dexamethasone with either a 5-HT3 receptor antagonist or an NK-1 receptor antagonist as well as other drugs as indicated) per approved product label.

Experimental: I-DXd + Opevesostat

Following a dose escalation regimen with I-DXd, participants will receive I-DXd at a determined dose until unacceptable toxicity, PD, death or withdrawal of consent PLUS opevesostat at a determined dose until any of the criterion for discontinuation of study intervention is met.

Administered via IV infusion at a specified dose on specified days

Outros nomes:
  • I-DXD, MK-2400, DS-7300A

Before each dose of I-DXd, participants are required to take premedication for prevention of nausea and vomiting with a 2- or 3-drug combination regimen (eg, dexamethasone with either a 5-HT3 receptor antagonist or an NK-1 receptor antagonist as well as other drugs as indicated) per approved product label.

Administered orally at a specified dose on specified days

Outros nomes:
  • MK-5684
  • ODM-208
Experimental: I-DXd +ARPI (Abiraterone or Enzalutamide)

Following a dose escalation regimen with I-DXd, participants will receive I-DXd at a determined dose until unacceptable toxicity, PD, death or withdrawal of consent PLUS ARPI (Androgen Receptor Pathway Inhibitor) - Abiraterone acetate OR Enzalutamide at a determined dose until any of the criterion for discontinuation of study intervention is met.

Administered via IV infusion at a specified dose on specified days

Outros nomes:
  • I-DXD, MK-2400, DS-7300A

Before each dose of I-DXd, participants are required to take premedication for prevention of nausea and vomiting with a 2- or 3-drug combination regimen (eg, dexamethasone with either a 5-HT3 receptor antagonist or an NK-1 receptor antagonist as well as other drugs as indicated) per approved product label.

Administered orally at a specified dose on specified days

Administered orally at a specified dose on specified days

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Efficacy Phase: Number of Participants Who Experience One or More Dose-Limiting Toxicities (DLTs) - Combination Arms Only
Prazo: Up to approximately 21 days

The following events if considered drug related by the Investigator, will be considered a DLT: Grade 4 nonhematologic toxicity (not based on laboratory value); Grade 4 hematologic toxicity lasting ≥7 days, except thrombocytopenia; Grade 4 thrombocytopenia of any duration; Grade 3 thrombocytopenia associated with clinically significant bleeding; Nonhematologic AEs ≥Grade 3 with exceptions; Grade 3 or Grade 4 non-hematologic laboratory values if requires medical intervention, leads to hospitalization, persists for >1 week, or results in a Drug-induced Liver Injury with exceptions; Grade 3 or 4 febrile neutropenia; Study intervention - related toxicities that lead to discontinuation of study treatment during Cycle 1; Prolonged delay (>2 weeks) in initiating Cycles 2 due to treatment-related toxicity; Missing >25% of study intervention doses as a result of treatment-related AE during Cycle 1; Grade 5 toxicity.

Up to approximately 21 days
Efficacy Phase: Number of Participants Who Experienced an Adverse Event (AE)
Prazo: Up to approximately 54 months

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.

Up to approximately 54 months
Efficacy Phase: Number of Participants Who Discontinued Study Intervention Due to an AE
Prazo: Up to approximately 24 months

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.

Up to approximately 24 months
Efficacy Phase: Prostate-Specific Antigen (PSA) response rate
Prazo: Up to approximately 54 months

PSA response is defined per prostate cancer working group (PCWG) criteria as a reduction in the PSA level of 50% or more from baseline measured at consecutive assessments at least 3 weeks apart.

Up to approximately 54 months
Safety Lead-in Phase: Number of Participants Who Experience One or More Dose-Limiting Toxicities (DLTs) - Combination Arms Only
Prazo: Up to approximately 21 days

The following events if considered drug related by the Investigator, will be considered a DLT: Grade 4 nonhematologic toxicity (not based on laboratory value); Grade 4 hematologic toxicity lasting ≥7 days, except thrombocytopenia; Grade 4 thrombocytopenia of any duration; Grade 3 thrombocytopenia associated with clinically significant bleeding; Nonhematologic AEs ≥Grade 3 with exceptions; Grade 3 or Grade 4 non-hematologic laboratory values if requires medical intervention, leads to hospitalization, persists for >1 week, or results in a Drug-induced Liver Injury with exceptions; Grade 3 or 4 febrile neutropenia; Study intervention - related toxicities that lead to discontinuation of study treatment during Cycle 1; Prolonged delay (>2 weeks) in initiating Cycles 2 due to treatment-related toxicity; Missing >25% of study intervention doses as a result of treatment-related AE during Cycle 1; Grade 5 toxicity.

Up to approximately 21 days
Safety Lead-in Phase: Number of Participants Who Experienced an Adverse Event (AE) - Combination Arms Only
Prazo: Up to approximately 21 days

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.

Up to approximately 21 days
Safety Lead-in Phase: Number of Participants Who Discontinued Study Intervention Due to an AE - Combination Arms Only
Prazo: Up to approximately 21 days

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.

Up to approximately 21 days

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Objective Response Rate (ORR)
Prazo: Up to approximately 54 months

ORR is defined as the percentage of participants with Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per PCWG3-Modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1). The percentage of participants who experience CR or PR as assessed by Blinded Independent Central Review (BICR) will be presented.

Up to approximately 54 months
Radiographic Progression-Free Survival (rPFS)
Prazo: Up to approximately 54 months

rPFS is defined as the time from randomization to the first documented progressive disease (PD) per PCWG3-modified RECIST 1.1 based on BICR or death due to any cause, whichever occurred first. Per PCWG3-modified RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions or ≥2 new bone lesions was also considered PD. PCWG3-modified RECIST is similar to RECIST 1.1 with the exception that a confirmation assessment of PD (>4 weeks after the initial PD) is required for participants who remain on treatment following a documented PD per RECIST 1.1 and PCWG3 rules include new bone lesions. The rPFS per PCWG3-modified RECIST as assessed by BICR for all participants is presented. The nonparametric Kaplan-Meier method will be used to estimate the rPFS curve in each treatment arm

Up to approximately 54 months
Overall Survival (OS)
Prazo: Up to approximately 54 months

Overall survival (OS) is defined as the time from randomization to death due to any cause. The nonparametric Kaplan-Meier method will be used to estimate the survival curves.

Up to approximately 54 months
Duration of Response (DOR)
Prazo: Up to approximately 54 months

DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per PCWG3-modified RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of ≥ 2 new bone lesions is also considered PD. DOR as assessed by BICR is presented. The nonparametric Kaplan-Meier method will be used to estimate the DOR in each treatment arm.

Up to approximately 54 months
Time from allocation/randomization to initiation of the first subsequent anticancer therapy (TFST)
Prazo: Up to approximately 54 months

TFST is defined as the time from randomization to initiation of the first subsequent anticancer therapy or death, whichever occurs first. The nonparametric Kaplan-Meier method will be used to estimate the TFST in each treatment arm.

Up to approximately 54 months
Time to Prostate-Specific Antigen (PSA) Progression
Prazo: Up to approximately 54 months

Time to PSA progression is defined as the time from randomization to PSA progression. Participants without PSA progression will be censored at the last PSA assessment date. The PSA progression date is defined as the date of:

1) ≥25% increase and ≥2 ng/mL above the nadir, confirmed by a second value ≥3 weeks later if there is PSA decline from baseline, OR 2) ≥25% increase and ≥2 ng/mL increase from baseline beyond 12 weeks if there is no PSA decline from baseline.

Up to approximately 54 months
Time to pain progression (TTPP)
Prazo: Up to approximately 54 months

The time from allocation/randomization to pain progression based on the Brief Pain Inventory-Short Form (BPI-SF) Item 3 "worst pain in 24 hours" and by the Analgesic Quantification Algorithm (AQA) score.

Up to approximately 54 months

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Colaboradores

Investigadores

  • Diretor de estudo: Medical Director, Merck Sharp & Dohme LLC

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

3 de julho de 2025

Conclusão Primária (Estimado)

1 de outubro de 2031

Conclusão do estudo (Estimado)

1 de outubro de 2031

Datas de inscrição no estudo

Enviado pela primeira vez

3 de março de 2025

Enviado pela primeira vez que atendeu aos critérios de CQ

3 de março de 2025

Primeira postagem (Real)

7 de março de 2025

Atualizações de registro de estudo

Última Atualização Postada (Real)

9 de outubro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

8 de outubro de 2026

Última verificação

1 de outubro de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever